prednisone has been researched along with Neonatal Alloimmune Thrombocytopenia in 7 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fetal and neonatal alloimmune thrombocytopenia is an alloimmune disorder resulting from platelet opsonization by maternal antibodies that destroy fetal platelets." | 5.46 | Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity. ( Gilman-Sachs, A; Kwak-Kim, J; Salazar Garcia, MD; Skariah, A; Sung, N; Tikoo, A; Wu, L, 2017) |
| "In this prospective, multicenter, randomized controlled study, 99 women with fetal-neonatal alloimmune thrombocytopenia whose prior affected child did not have an intracranial hemorrhage were randomized to receive an intensive intravenous gammaglobulin-based regimen: 2 g/kg per week or intravenous gammaglobulin 1 g/kg per week plus prednisone 0." | 5.22 | Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. ( Berkowitz, RL; Bussel, JB; Ferd, P; Gabor, J; Jin, JC; Lakkaraja, M; Manotas, KC; McFarland, JG; Vinograd, CA; Wissert, M, 2016) |
| " Current management of fetal and neonatal alloimmune thrombocytopenia in a subsequent affected pregnancy involves antenatal administration of intravenous immune globulin and prednisone to the pregnant woman to prevent the development of severe fetal thrombocytopenia and secondary intracranial hemorrhage in utero." | 5.12 | New developments in fetal and neonatal alloimmune thrombocytopenia. ( Berkowitz, RL; Bussel, JB; Vander Haar, EL, 2021) |
| "A survey was mailed to 62 women treated by one provider from 2005 to 2013 asking if they experienced side effects from IVIG and prednisone, if their lives were negatively affected, if they would plan another affected pregnancy and if they needed help managing side effects." | 3.83 | Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. ( Lehman, KJ; O'Shaughnessy, RW; Rossi, KQ, 2016) |
| "Fetal and neonatal alloimmune thrombocytopenia is an alloimmune disorder resulting from platelet opsonization by maternal antibodies that destroy fetal platelets." | 1.46 | Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity. ( Gilman-Sachs, A; Kwak-Kim, J; Salazar Garcia, MD; Skariah, A; Sung, N; Tikoo, A; Wu, L, 2017) |
| "Severe neonatal thrombocytopenia below 50 × 10(9) /l is reported in 8-13% of the neonates from mothers with ITP and intracranial haemorrhage (ICH) in 0-2·9%." | 1.39 | Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. ( Brand, A; Lopriore, E; van der Lugt, NM; van Kampen, A; Walther, FJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bussel, JB | 4 |
| Vander Haar, EL | 1 |
| Berkowitz, RL | 3 |
| van der Lugt, NM | 1 |
| van Kampen, A | 1 |
| Walther, FJ | 1 |
| Brand, A | 1 |
| Lopriore, E | 1 |
| Rossi, KQ | 1 |
| Lehman, KJ | 1 |
| O'Shaughnessy, RW | 1 |
| Lakkaraja, M | 2 |
| Vinograd, CA | 2 |
| Manotas, KC | 2 |
| Jin, JC | 2 |
| Ferd, P | 2 |
| Gabor, J | 2 |
| Wissert, M | 2 |
| McFarland, JG | 2 |
| Skariah, A | 1 |
| Sung, N | 1 |
| Salazar Garcia, MD | 1 |
| Wu, L | 1 |
| Tikoo, A | 1 |
| Gilman-Sachs, A | 1 |
| Kwak-Kim, J | 1 |
| Rayment, R | 1 |
| Brunskill, SJ | 1 |
| Soothill, PW | 1 |
| Roberts, DJ | 1 |
| Murphy, MF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Multicenter Trial of Antenatal Treatment of Alloimmune Thrombocytopenia[NCT00194987] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of ICH assessed by fetal and neonatal ultrasound with MRI back up most commonly in utero so range from 20-40 weeks fo gestation (NCT00194987)
Timeframe: time of ICH (range 20-40 wks)
| Intervention | number of newborns with ICH (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 0 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 0 |
Number of Fetal Platelet Counts > 50,000/uL Among Those Who Underwent Fetal Blood Sampling and Had a Fetal Platelet Count Determined (NCT00194987)
Timeframe: 32 +/- 2 weeks
| Intervention | number newborns with >50,000 pats (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 44 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 43 |
this uses the birth platelet count of the fetuses from the study when they are born (NCT00194987)
Timeframe: 32-40 weeks (the endpoint is the birth which is not at the same number of weeks for all of the babies. This is why the weeks are not listed specifically eg week 40
| Intervention | number of newborns with >50,000 pets (Number) |
|---|---|
| IVIG 1g/kg Twice Per Week | 48 |
| IVIG 1g/k/Week and Prednisone 0.5 mg/kg/Day | 47 |
2 reviews available for prednisone and Neonatal Alloimmune Thrombocytopenia
| Article | Year |
|---|---|
New developments in fetal and neonatal alloimmune thrombocytopenia.
Topics: Antigens, Human Platelet; Cell-Free Nucleic Acids; Drug Development; Female; Genotype; Glucocorticoi | 2021 |
Antenatal interventions for fetomaternal alloimmune thrombocytopenia.
Topics: Antigens, Human Platelet; Dexamethasone; Female; Fetal Diseases; Glucocorticoids; Humans; Immunoglob | 2011 |
2 trials available for prednisone and Neonatal Alloimmune Thrombocytopenia
| Article | Year |
|---|---|
Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia.
Topics: Cordocentesis; Female; Fetal Blood; Gestational Age; Humans; Immunoglobulins, Intravenous; Immunolog | 2016 |
Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
Topics: Anemia; Blood Group Antigens; Female; Hemoglobins; Humans; Immunoglobulins, Intravenous; Mothers; Pr | 2016 |
3 other studies available for prednisone and Neonatal Alloimmune Thrombocytopenia
| Article | Year |
|---|---|
Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura.
Topics: Adult; Blood Platelets; Female; Humans; Immunoglobulins, Intravenous; Infant, Newborn; Platelet Coun | 2013 |
Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle.
Topics: Adult; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Life Style; Prednisone; Pregna | 2016 |
Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity.
Topics: Adult; Antigens, Human Platelet; Female; Humans; Immunoglobulin G; Prednisone; Pregnancy; Risk; Th1 | 2017 |